KemPharm (KMPH) – Major News
-
KemPharm (KMPH) Reports In-Line Q3 EPS
-
KemPharm (KMPH) Misses Q2 EPS by 56c
-
KemPharm (KMPH) Reports FDA Approval of Apadaz for Short-Term Management of Acute Pain
-
KemPharm (KMPH) Receives FDA Complete Response Letter for Apadaz NDA
-
KemPharm (KMPH) Tops Q1 EPS by 26c
-
KemPharm (KMPH) Receives Mixed FDA Panel Vote on Apadaz; Issues Commentary
-
KemPharm (KMPH) Misses Q4 EPS by 14c
-
KemPharm (KMPH) Misses Q3 EPS by 26c
-
KemPharm (KMPH) Says Clinical Trial Reaffirms Properties of KP201/APAP
-
KemPharm (KMPH) Reports Q2 Loss Per Share of $2.45
-
KemPharm (KMPH) Reports Positive Data From Intranasal Human Abuse Liability Study of KP201/APAP
-
KemPharm (KMPH) IPO Opens Up 7%
Back to KMPH Stock Lookup